Published in Cancer Weekly, September 28th, 2004
Optimal treatment for splenic MZL "is not clearly established," scientists in Italy explained. "Splenectomy has been proposed as the treatment of choice in patients with cytopenias and/or symptoms caused by an enlarged spleen."
"Splenic MZL, which expresses the CD20 antigen on tumor cell surfaces, is a disease entity candidate to treatment with anti-CD20 monoclonal antibodies," noted L. Arcaini and colleagues at the University of Pavia.
In their study, the collaborators "employed an immunochemotherapy regimen with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.